Adjuvant Toripalimab Better Tolerated Than HDI in Mucosal Melanoma
Toripalimab is similarly effective but safer than high-dose interferon-α2b for patients with resected mucosal melanoma, a new study suggests.
Skin Cancer
Illegitimate Online Pharmacies May Put Cancer Patients at Risk
Illegitimate online pharmacies are selling imatinib without a prescription, making false claims about being registered with regulatory bodies, and failing to provide patients with drug-related warnings.
AI and Dermatologists Similarly Judge Melanoma Thickness
Readers most accurately discriminated between thin (≤1.0 mm) and thick melanomas (>1.0 mm).
Medically Integrated Dispensing on the Rise in US Oncology Practices
From 2010 to 2019, the percentage of oncology practices with medically integrated dispensing more than doubled.
Essential Oils Show Promise for Some Symptoms of Infusion-Based Cancer Treatments
Researchers sought to determine the efficacy of essential oil use for relief of symptom burden in patients receiving infusion-based therapy for GI, neuroendocrine, or skin cancer.
Neural Network-Based Model Shows Potential to Decrease SLN Biopsy Rate, Costs in Melanoma Subtypes
A decision-analytic study sought to identify an effective model for predicting risk for SLN biopsy and metastasis in patients with cutaneous melanoma.
Mohs Surgery May Be Appropriate for Many Patients Older than 85 Years
A prospective study investigated the factors that determine whether Mohs surgery is efficacious in patients older than 85 with skin cancer.
Factors ID’d for Self-Exam Compliance Among Melanoma Patients
Younger age, female sex, increased disease severity, and having a significant other to help with exams may improve compliance.
Incidence of Melanoma Diagnosis, Biopsy Parallel Skin Screening Uptake
Researchers sought to determine if the incidence of melanoma diagnoses and biopsies increased with a greater uptake of skin screenings.
Risk of Cancer-Specific Death May Remain Elevated for 30 Years
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
- Loading...
Loading...
Next post in General Oncology
Loading... 
Loading...